Last modified: December 20, 2022
Quick Facts
  • certificate with a ribbon icon below
    • Xavier Bichat Medical School, Paris, France
    • Post-Doctoral Research Fellow, Harvard Medical School
  • membership card and identification icon
    • European Association for Cardio-Thoracic Surgery
    • European Society of Thoracic Surgeons
    • International Mesothelioma Interest Group
    • International Association for the Study of Lung Cancer
  • plus sign in a circle icon
    • Pleural Mesothelioma
    • Mesothelioma Surgery
    • Research

About Dr. Lang-Lazdunski

Although he is recognized as one of the world’s foremost authorities on mesothelioma surgery, Dr. Loic Lang-Lazdunski believes it takes a specialty center with multidisciplinary expertise to treat the cancer optimally.

“It’s the collaboration with experts in all the fields that will make us successful with these patients,” he said. “It’s the personalization of the treatment and the extensive experience from pulmonologists, surgeons, oncologists, pathologists, anesthetists and nurses on staff.”

Lang-Lazdunski came to Quebec after 12 years as a consultant thoracic surgeon at Guy’s and St. Thomas’ NHS Foundation Trust in London. He became professor of thoracic surgery at King’s College, London, with a chair in mesothelioma in 2012.

In 2022, Lang-Lazdunski published research showing that cancer-directed surgery, systemic chemotherapy and prophylactic radiotherapy may provide a significant survival benefit in selected mesothelioma patients.

His extensive experience in treating pleural mesothelioma — and his success — has led to an international following. He contributes regularly to the European Lung Cancer Congress, World Conference on Lung Cancer, International Mesothelioma Interest Group, American Society of Clinical Oncology, the European Society of Thoracic Surgeons and The Mesothelioma Center at, the nation’s most trusted mesothelioma resource.

Lang-Lazdunski collaborates with prominent specialists worldwide and has contributed several landmark studies that have helped improve both treatment and prognosis of pleural mesothelioma.